Towards Personalized Management of Sarcopenia in COPD

References

• Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–991S. doi:10.1093/jn/127.5.990S
   PubMed Web of Science ®Google Scholar
• Schols AM, Mostert R, Soeters PB, Wouters EF. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax. 1991;46(10):695–699. doi:10.1136/thx.46.10.695
   PubMed Web of Science ®Google Scholar
• Schols AM, Mostert R, Soeters PB, Greve LH, Wouters EF. Nutritional state and exercise performance in patients with chronic obstructive lung disease. Thorax. 1989;44(11):937–941. doi:10.1136/thx.44.11.937
   PubMed Web of Science ®Google Scholar
• Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2019;28(154):190049. doi:10.1183/16000617.0049-2019
   PubMed Web of Science ®Google Scholar
• Maltais F, Decramer M, Casaburi R, et al. An official American thoracic society/European respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–e62. doi:10.1164/rccm.201402-0373ST
   PubMed Web of Science ®Google Scholar
• Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global initiative for chronic obstructive lung disease: the changes made. Cureus. 2019;11(6):e4985.
   PubMed Web of Science ®Google Scholar
• Jones SE, Maddocks M, Kon SSC, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–218. doi:10.1136/thoraxjnl-2014-206440
   PubMed Web of Science ®Google Scholar
• Papadopoulou SK, Tsintavis P, Potsaki P, Papandreou D. Differences in the prevalence of sarcopenia in community-dwelling, nursing home and hospitalized individuals. a systematic review and meta-analysis. J Nutr Health Aging. 2020;24(1):83–90. doi:10.1007/s12603-019-1267-x
   PubMed Web of Science ®Google Scholar
• Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–256. doi:10.1016/j.jamda.2011.01.003
   PubMed Web of Science ®Google Scholar
• Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol a Biol Sci Med Sci. 2014;69(5):547–558. doi:10.1093/gerona/glu010
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307e302. doi:10.1016/j.jamda.2019.12.012
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423. doi:10.1093/ageing/afq034
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799. doi:10.1016/j.clnu.2008.06.013
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Rolland Y, Van Kan GA, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care. 2011;14(1):15–21. doi:10.1097/MCO.0b013e328340c2c2
   PubMed Web of Science ®Google Scholar
• Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and its clinical correlates in the general population: the rotterdam study. J Bone Miner Res. 2018;33(7):1209–1218. doi:10.1002/jbmr.3416
   PubMed Web of Science ®Google Scholar
• Sepulveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020. doi:10.1002/jcsm.12600
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the international sarcopenia initiative (EWGSOP and IWGS). Age Ageing. 2014;43(6):748–759. doi:10.1093/ageing/afu115
   PubMed Web of Science ®Google Scholar
• Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16(1):21. doi:10.1186/s40200-017-0302-x
   PubMedGoogle Scholar
• Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the copenhagen city heart study. Am J Respir Crit Care Med. 2006;173(1):79–83. doi:10.1164/rccm.200506-969OC
   PubMed Web of Science ®Google Scholar
• Davalos-Yerovi V, Marco E, Sanchez-Rodriguez D, et al. Sarcopenia according to the revised European consensus on definition and diagnosis (EWGSOP2) criteria predicts hospitalizations and long-term mortality in rehabilitation patients with stable chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2019;20(8):1047–1049. doi:10.1016/j.jamda.2019.03.019
   PubMed Web of Science ®Google Scholar
• Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–59. doi:10.1093/ajcn/82.1.53
   PubMed Web of Science ®Google Scholar
• Puhan MA, Siebeling L, Zoller M, Muggensturm P, Ter Riet G. Simple functional performance tests and mortality in COPD. Eur Respir J. 2013;42(4):956–963. doi:10.1183/09031936.00131612
   PubMed Web of Science ®Google Scholar
• Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the prospective urban rural epidemiology (PURE) study. Lancet. 2015;386(9990):266–273. doi:10.1016/S0140-6736(14)62000-6
   PubMed Web of Science ®Google Scholar
• Hakamy A, Bolton CE, Gibson JE, McKeever TM. Risk of fall in patients with COPD. Thorax. 2018;73(11):1079–1080. doi:10.1136/thoraxjnl-2017-211008
   PubMed Web of Science ®Google Scholar
• Adas-Okuma MG, Maeda SS, Gazzotti MR, et al. COPD as an independent risk factor for osteoporosis and fractures. Osteoporos Int. 2020;31(4):687–697. doi:10.1007/s00198-019-05235-9
   PubMed Web of Science ®Google Scholar
• Lee DW, Choi EY, Wu Q. Sarcopenia as an independent risk factor for decreased BMD in COPD patients: Korean national health and nutrition examination surveys IV and V (2008–2011). PLoS One. 2016;11(10):e0164303. doi:10.1371/journal.pone.0164303
   PubMed Web of Science ®Google Scholar
• Beaudart C, Biver E, Reginster J-Y, et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8(2):238–244. doi:10.1002/jcsm.12149
   PubMed Web of Science ®Google Scholar
• Suleymanova A, Baranova I, Brodskaya O, et al. Quality of life in COPD patients with sarcopenia. Eur Respir J. 2019;54.
   Google Scholar
• Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. what we know and can do for our patients. Am J Respir Crit Care Med. 2018;198(2):175–186. doi:10.1164/rccm.201710-2140CI
   PubMed Web of Science ®Google Scholar
• Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia. Clin Geriatr Med. 2017;33(1):17–26. doi:10.1016/j.cger.2016.08.002
   PubMed Web of Science ®Google Scholar
• Rolland Y, Czerwinski S. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12(7):433–450.
   PubMed Web of Science ®Google Scholar
• Kwan P. Sarcopenia, a neurogenic syndrome? J Aging Res. 2013;2013:791679. doi:10.1155/2013/791679
   PubMedGoogle Scholar
• Perrot L, Greil A, Boirie Y, et al. Prevalence of sarcopenia and malnutrition during acute exacerbation of COPD and after 6 months recovery. Eur J Clin Nutr. 2020;74(11):1556–1564. doi:10.1038/s41430-020-0623-6
   PubMed Web of Science ®Google Scholar
• Langen RC, Gosker HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013;45(10):2245–2256. doi:10.1016/j.biocel.2013.06.015
   PubMed Web of Science ®Google Scholar
• Abdulai RM, Jensen TJ, Patel NR, et al. Deterioration of limb muscle function during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(4):433–449. doi:10.1164/rccm.201703-0615CI
   PubMed Web of Science ®Google Scholar
• Theriault ME, Pare ME, Maltais F, Debigare R. Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One. 2012;7(6):e39124. doi:10.1371/journal.pone.0039124
   PubMed Web of Science ®Google Scholar
• Barreiro E, Salazar-Degracia A, Sancho-Munoz A, Gea J. Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases. J Cell Physiol. 2019;234(7):11315–11329. doi:10.1002/jcp.27789
   PubMed Web of Science ®Google Scholar
• Guo Y, Gosker HR, Schols AM, et al. Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(11):1313–1320. doi:10.1164/rccm.201304-0732OC
   PubMed Web of Science ®Google Scholar
• Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The neuromuscular junction: aging at the crossroad between nerves and muscle. Front Aging Neurosci. 2014;6:208. doi:10.3389/fnagi.2014.00208
   PubMed Web of Science ®Google Scholar
• Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985). 2013;114(9):1253–1262. doi:10.1152/japplphysiol.00790.2012
   PubMed Web of Science ®Google Scholar
• Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1414–1418. doi:10.1164/ajrccm.164.8.2008109
   PubMed Web of Science ®Google Scholar
• Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:669–675. doi:10.2147/COPD.S130790
   PubMed Web of Science ®Google Scholar
• Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest. 2007;37(11):897–904. doi:10.1111/j.1365-2362.2007.01867.x
   PubMed Web of Science ®Google Scholar
• Barreiro E, Schols AM, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008;63(2):100–107. doi:10.1136/thx.2007.078030
   PubMed Web of Science ®Google Scholar
• Larsson L, Ansved T. Effects of long-term physical training and detraining on enzyme histochemical and functional skeletal muscle characteristic in man. Muscle Nerve. 1985;8(8):714–722. doi:10.1002/mus.880080815
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16. doi:10.1164/ajrccm.150.1.8025735
   PubMed Web of Science ®Google Scholar
• Hanada M, Sakamoto N, Ishimatsu Y, et al. Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology. 2016;21(6):1088–1093. doi:10.1111/resp.12807
   PubMed Web of Science ®Google Scholar
• Minetto MA, Qaisar R, Agoni V, et al. Quantitative and qualitative adaptations of muscle fibers to glucocorticoids. Muscle Nerve. 2015;52(4):631–639. doi:10.1002/mus.24572
   PubMed Web of Science ®Google Scholar
• Fappi A, Neves JC, Sanches LN, et al. Skeletal muscle response to deflazacort, dexamethasone and methylprednisolone. Cells. 2019;8(5):406. doi:10.3390/cells8050406
   PubMed Web of Science ®Google Scholar
• Koerts-de Lang E, Schols AM, Rooyackers OE, Gayan-Ramirez G, Decramer M, Wouters EF. Different effects of corticosteroid-induced muscle wasting compared with undernutrition on rat diaphragm energy metabolism. Eur J Appl Physiol. 2000;82(5–6):493–498. doi:10.1007/s004210000231
   PubMed Web of Science ®Google Scholar
• Pouw EM, Koerts-de Lang E, Gosker HR, et al. Muscle metabolic status in patients with severe COPD with and without long-term prednisolone. Eur Respir J. 2000;16(2):247–252. doi:10.1034/j.1399-3003.2000.16b11.x
   PubMed Web of Science ®Google Scholar
• Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European respiratory society statement. Eur Respir J. 2014;44(6):1504–1520. doi:10.1183/09031936.00070914
   PubMed Web of Science ®Google Scholar
• Beaudart C, Sanchez-Rodriguez D, Locquet M, Reginster JY, Lengele L, Bruyere O. Malnutrition as a strong predictor of the onset of sarcopenia. Nutrients. 2019;11(12):2883. doi:10.3390/nu11122883
   PubMed Web of Science ®Google Scholar
• Houston DK, Nicklas BJ, Ding J, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the health, aging, and body composition (health ABC) study. Am J Clin Nutr. 2008;87(1):150–155.
   PubMed Web of Science ®Google Scholar
• de Theije CC, Langen RC, Lamers WH, Schols AM, Kohler SE. Distinct responses of protein turnover regulatory pathways in hypoxia- and semistarvation-induced muscle atrophy. Am J Physiol Lung Cell Mol Physiol. 2013;305(1):L82–91. doi:10.1152/ajplung.00354.2012
   PubMed Web of Science ®Google Scholar
• Debevec T, Ganse B, Mittag U, Eiken O, Mekjavic IB, Rittweger J. Hypoxia aggravates inactivity-related muscle wasting. Front Physiol. 2018;9:494. doi:10.3389/fphys.2018.00494
   PubMed Web of Science ®Google Scholar
• Kneppers AEM, Langen RCJ, Gosker HR, et al. Increased myogenic and protein turnover signaling in skeletal muscle of chronic obstructive pulmonary disease patients with sarcopenia. J Am Med Dir Assoc. 2017;18(7):637 e631–637 e611. doi:10.1016/j.jamda.2017.04.016
   Web of Science ®Google Scholar
• Sanders KJ, Kneppers AE, van de Bool C, Langen RC, Schols AM. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 2016;7(1):5–22. doi:10.1002/jcsm.12062
   PubMed Web of Science ®Google Scholar
• Ju C-R, Chen R-C. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med. 2012;106(1):102–108. doi:10.1016/j.rmed.2011.07.016
   PubMed Web of Science ®Google Scholar
• Leermakers PA, Gosker HR. Skeletal muscle mitophagy in chronic disease: implications for muscle oxidative capacity? Curr Opin Clin Nutr Metab Care. 2016;19(6):427–433. doi:10.1097/MCO.0000000000000319
   PubMed Web of Science ®Google Scholar
• Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007;62(11):944–949. doi:10.1136/thx.2007.078980
   PubMed Web of Science ®Google Scholar
• van de Bool C, Gosker HR, van den Borst B, Op den Kamp CM, Slot IGM, Schols AMWJ. Muscle quality is more impaired in sarcopenic patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17(5):415–420. doi:10.1016/j.jamda.2015.12.094
   PubMed Web of Science ®Google Scholar
• Krzyminska-Siemaszko R, Tobis S, Lewandowicz M, Wieczorowska-Tobis K. Comparison of four sarcopenia screening questionnaires in community-dwelling older adults from Poland using six sets of international diagnostic criteria of sarcopenia. PLoS One. 2020;15(4):e0231847. doi:10.1371/journal.pone.0231847
   PubMed Web of Science ®Google Scholar
• Hajaoui M, Locquet M, Beaudart C, Reginster J-Y, Petermans J, Bruyère O. Sarcopenia: performance of the SARC-F questionnaire according to the european consensus criteria, EWGSOP1 and EWGSOP2. J Am Med Dir Assoc. 2019;20(9):1182–1183. doi:10.1016/j.jamda.2019.05.021
   PubMed Web of Science ®Google Scholar
• Bahat G, Yilmaz O, Kılıç C, Oren MM, Karan MA. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging. 2018;22(8):898–903. doi:10.1007/s12603-018-1067-8
   PubMed Web of Science ®Google Scholar
• Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK, Gonzalez MC. Enhancing SARC-F: improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc. 2016;17(12):1136–1141.
   PubMed Web of Science ®Google Scholar
• Kashani KB, Frazee EN, Kukralova L, et al. Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index. Crit Care Med. 2017;45(1):e23–e29. doi:10.1097/CCM.0000000000002013
   PubMedGoogle Scholar
• Amado CA, Garcia-Unzueta MT, Lavin BA, et al. The ratio serum creatinine/serum cystatin C (a surrogate marker of muscle mass) as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients. Respiration. 2019;97(4):302–309. doi:10.1159/000494296
   PubMed Web of Science ®Google Scholar
• Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin Nutr. 2020. doi:10.1016/j.clnu.2020.08.010
   PubMed Web of Science ®Google Scholar
• Tang T, Zhuo Y, Xie L, Wang H, Yang M. Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients. Sci Rep. 2020;10(1):1260. doi:10.1038/s41598-020-58304-z
   PubMed Web of Science ®Google Scholar
• Lien YH. Looking for sarcopenia biomarkers. Am J Med. 2017;130(5):502–503. doi:10.1016/j.amjmed.2017.01.018
   PubMed Web of Science ®Google Scholar
• Trudzinski FC, Alqudrah M, Omlor A, et al. Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):151. doi:10.1186/s12931-019-1107-x
   PubMed Web of Science ®Google Scholar
• Kanda K, Sakuma J, Akimoto T, Kawakami Y, Suzuki K. Detection of titin fragments in urine in response to exercise-induced muscle damage. PLoS One. 2017;12(7):e0181623. doi:10.1371/journal.pone.0181623
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Tsutsumi R, Hara K, et al. Urinary titin is a novel biomarker for muscle atrophy in nonsurgical critically ill patients: a two-center, prospective observational study. Crit Care Med. 2020;48(9):1327–1333. doi:10.1097/CCM.0000000000004486
   PubMed Web of Science ®Google Scholar
• Beaudart C, McCloskey E, Bruyère O, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):170. doi:10.1186/s12877-016-0349-4
   PubMed Web of Science ®Google Scholar
• Borga M, West J, Bell JD, et al. Advanced body composition assessment: from body mass index to body composition profiling. J Investig Med. 2018;66(5):1–9. doi:10.1136/jim-2018-000722
   PubMed Web of Science ®Google Scholar
• Karlsson A, Rosander J, Romu T, et al. Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water-fat MRI. J Magn Reson Imaging. 2015;41(6):1558–1569. doi:10.1002/jmri.24726
   PubMed Web of Science ®Google Scholar
• West J, Dahlqvist Leinhard O, Romu T, et al. Feasibility of MR-based body composition analysis in large scale population studies. PLoS One. 2016;11(9):e0163332. doi:10.1371/journal.pone.0163332
   PubMed Web of Science ®Google Scholar
• Schweitzer L, Geisler C, Pourhassan M, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? Am J Clin Nutr. 2015;102(1):58–65. doi:10.3945/ajcn.115.111203
   PubMed Web of Science ®Google Scholar
• Lee K, Shin Y, Huh J, et al. Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol. 2019;20(2):205–217. doi:10.3348/kjr.2018.0479
   PubMed Web of Science ®Google Scholar
• Engelke K, Museyko O, Wang L, Laredo JD. Quantitative analysis of skeletal muscle by computed tomography imaging-State of the art. J Orthop Translat. 2018;15:91–103. doi:10.1016/j.jot.2018.10.004
   PubMed Web of Science ®Google Scholar
• Albano D, Messina C, Vitale J, Sconfienza LM. Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2020;30(4):2199–2208. doi:10.1007/s00330-019-06573-2
   PubMed Web of Science ®Google Scholar
• Sanders KJC, Degens J, Dingemans AC, Schols A. Cross-sectional and longitudinal assessment of muscle from regular chest computed tomography scans: L1 and pectoralis muscle compared to L3 as reference in non-small cell lung cancer. Int J Chron Obstruct Pulmon Dis. 2019;14:781–789. doi:10.2147/COPD.S194003
   PubMed Web of Science ®Google Scholar
• Amini B, Boyle SP, Boutin RD, Lenchik L. Approaches to assessment of muscle mass and myosteatosis on computed tomography: a systematic review. J Gerontol a Biol Sci Med Sci. 2019;74(10):1671–1678. doi:10.1093/gerona/glz034
   PubMed Web of Science ®Google Scholar
• McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc. 2014;11(3):326–334. doi:10.1513/AnnalsATS.201307-229OC
   PubMedGoogle Scholar
• Tanimura K, Sato S, Fuseya Y, et al. Quantitative assessment of erector spinae muscles in patients with chronic obstructive pulmonary disease. novel chest computed tomography-derived index for prognosis. Ann Am Thorac Soc. 2016;13(3):334–341. doi:10.1513/AnnalsATS.201507-446OC
   PubMed Web of Science ®Google Scholar
• Buckinx F, Landi F, Cesari M, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018;9(2):269–278. doi:10.1002/jcsm.12268
   PubMed Web of Science ®Google Scholar
• Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest. 2019;156(6):1092–1110. doi:10.1016/j.chest.2019.06.036
   PubMed Web of Science ®Google Scholar
• Ofenheimer A, Breyer-Kohansal R, Hartl S, et al. Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18–81 years-results from the LEAD cohort. Eur J Clin Nutr. 2020;74(8):1181–1191. doi:10.1038/s41430-020-0596-5
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Gonzalez MC, Lu J, et al. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc. 2015;74(4):355–366. doi:10.1017/S0029665115000129
   PubMed Web of Science ®Google Scholar
• Rutten EP, Spruit MA, Wouters EF. Critical view on diagnosing muscle wasting by single-frequency bio-electrical impedance in COPD. Respir Med. 2010;104(1):91–98. doi:10.1016/j.rmed.2009.07.004
   PubMed Web of Science ®Google Scholar
• Franssen FM, Rutten EP, Groenen MT, Vanfleteren LE, Wouters EF, Spruit MA. New reference values for body composition by bioelectrical impedance analysis in the general population: results from the UK Biobank. J Am Med Dir Assoc. 2014;15(6):448 e441–446. doi:10.1016/j.jamda.2014.03.012
   Web of Science ®Google Scholar
• Lee JE, Chun H, Kim YS, et al. Association between timed up and go test and subsequent functional dependency. J Korean Med Sci. 2020;35(3):e25–e25. doi:10.3346/jkms.2020.35.e25
   PubMed Web of Science ®Google Scholar
• Landi F, Onder G, Russo A, et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014;33(3):539–544. doi:10.1016/j.clnu.2013.07.013
   PubMed Web of Science ®Google Scholar
• Marklund S, Bui KL, Nyberg A. Measuring and monitoring skeletal muscle function in COPD: current perspectives. Int J Chron Obstruct Pulmon Dis. 2019;14:1825–1838. doi:10.2147/COPD.S178948
   PubMed Web of Science ®Google Scholar
• Canavan JL, Maddocks M, Nolan CM, et al. Functionally relevant cut point for isometric quadriceps muscle strength in chronic respiratory disease. Am J Respir Crit Care Med. 2015;192(3):395–397. doi:10.1164/rccm.201501-0082LE
   PubMed Web of Science ®Google Scholar
• Martin HJ, Yule V, Syddall HE, Dennison EM, Cooper C, Aihie Sayer A. Is hand-held dynamometry useful for the measurement of quadriceps strength in older people? A comparison with the gold standard Bodex dynamometry. Gerontology. 2006;52(3):154–159. doi:10.1159/000091824
   PubMed Web of Science ®Google Scholar
• Nyberg A, Saey D, Maltais F. Why and how limb muscle mass and function should be measured in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(9):1269–1277. doi:10.1513/AnnalsATS.201505-278PS
   PubMed Web of Science ®Google Scholar
• Karagiannis C, Savva C, Korakakis V, et al. Test-retest reliability of handgrip strength in patients with chronic obstructive pulmonary disease. COPD. 2020;1–7.
   Google Scholar
• Spruit MA, Sillen MJ, Groenen MT, Wouters EF, Franssen FM. New normative values for handgrip strength: results from the UK Biobank. J Am Med Dir Assoc. 2013;14(10):775 e775–711. doi:10.1016/j.jamda.2013.06.013
   Web of Science ®Google Scholar
• Dodds RM, Syddall HE, Cooper R, et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014;9(12):e113637–e113637. doi:10.1371/journal.pone.0113637
   PubMed Web of Science ®Google Scholar
• Alley DE, Shardell MD, Peters KW, et al. Grip strength cutpoints for the identification of clinically relevant weakness. J Gerontol a Biol Sci Med Sci. 2014;69(5):559–566. doi:10.1093/gerona/glu011
   PubMed Web of Science ®Google Scholar
• Vasconcelos K, Dias JMD, Bastone A, et al. Handgrip strength cutoff points to identify mobility limitation in community-dwelling older people and associated factors. J Nutr Health Aging. 2016;20(3):306–315. doi:10.1007/s12603-015-0584-y
   PubMed Web of Science ®Google Scholar
• Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57(2):251–259. doi:10.1111/j.1532-5415.2008.02126.x
   PubMed Web of Science ®Google Scholar
• Lage V, Silva GPD, Lacerda ACR, et al. Functional tests associated with sarcopenia in moderate chronic obstructive pulmonary disease. Expert Rev Respir Med. 2020. doi:10.1080/17476348.2021.1850276
   PubMed Web of Science ®Google Scholar
• Jones SE, Kon SSC, Canavan JL, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax. 2013;68(11):1015–1020. doi:10.1136/thoraxjnl-2013-203576
   PubMed Web of Science ®Google Scholar
• Lee L, Patel T, Costa A, et al. Screening for frailty in primary care: accuracy of gait speed and hand-grip strength. Can Fam Physician. 2017;63(1):e51–e57.
   PubMed Web of Science ®Google Scholar
• Kon SS, Canavan JL, Nolan CM, et al. The 4-metre gait speed in COPD: responsiveness and minimal clinically important difference. Eur Respir J. 2014;43(5):1298–1305. doi:10.1183/09031936.00088113
   PubMed Web of Science ®Google Scholar
• Pavasini R, Guralnik J, Brown JC, et al. Short physical performance battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14(1):215. doi:10.1186/s12916-016-0763-7
   PubMed Web of Science ®Google Scholar
• Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther. 2006;29(2):64–68. doi:10.1519/00139143-200608000-00004
   PubMedGoogle Scholar
• Al Haddad MA, John M, Hussain S, Bolton CE. Role of the timed up and go test in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2016;36(1):49–55. doi:10.1097/HCR.0000000000000143
   PubMed Web of Science ®Google Scholar
• Kovelis D, Gomes ARS, Mazzarin C, de Miranda A, Valderramas S. Association between the results of the timed up-and-go test adjusted for disease severity and sarcopenia in patients with chronic obstructive pulmonary disease: a pilot study. Clinics (Sao Paulo). 2019;74:e930–e930. doi:10.6061/clinics/2019/e930
   PubMed Web of Science ®Google Scholar
• Mesquita R, Wilke S, Smid DE, et al. Measurement properties of the timed up & go test in patients with COPD. Chron Respir Dis. 2016;13(4):344–352. doi:10.1177/1479972316647178
   PubMed Web of Science ®Google Scholar
• Bergland A, Jørgensen L, Emaus N, Strand BH. Mobility as a predictor of all-cause mortality in older men and women: 11.8 year follow-up in the tromsø study. BMC Health Serv Res. 2017;17(1):22. doi:10.1186/s12913-016-1950-0
   PubMedGoogle Scholar
• Hansen H, Beyer N, Frølich A, Godtfredsen N, Bieler T. Intra- and inter-rater reproducibility of the 6-minute walk test and the 30-second sit-to-stand test in patients with severe and very severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3447–3457. doi:10.2147/COPD.S174248
   PubMed Web of Science ®Google Scholar
• Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest. 2020;157(3):603–611. doi:10.1016/j.chest.2019.10.014
   PubMed Web of Science ®Google Scholar
• Celli B, Tetzlaff K, Criner G, et al. The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool. insights from the COPD biomarker qualification consortium. Am J Respir Crit Care Med. 2016;194(12):1483–1493. doi:10.1164/rccm.201508-1653OC
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab. 2019;26(2):65–74. doi:10.11005/jbm.2019.26.2.65
   PubMedGoogle Scholar
• McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793.
   PubMed Web of Science ®Google Scholar
• Marillier M, Bernard AC, Verges S, Neder JA. Locomotor muscles in COPD: the rationale for rehabilitative exercise training. Front Physiol. 2019;10:1590. doi:10.3389/fphys.2019.01590
   PubMed Web of Science ®Google Scholar
• Spruit MA, Singh SJ, Garvey C, et al. An official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64. doi:10.1164/rccm.201309-1634ST
   PubMed Web of Science ®Google Scholar
• Passey SL, Hansen MJ, Bozinovski S, McDonald CF, Holland AE, Vlahos R. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther. 2016;166:56–70. doi:10.1016/j.pharmthera.2016.06.013
   PubMed Web of Science ®Google Scholar
• Zeng Y, Jiang F, Chen Y, Chen P, Cai S. Exercise assessments and trainings of pulmonary rehabilitation in COPD: a literature review. Int J Chron Obstruct Pulmon Dis. 2018;13:2013–2023. doi:10.2147/COPD.S167098
   PubMed Web of Science ®Google Scholar
• Morris NR, Walsh J, Adams L, Alision J. Exercise training in COPD: what is it about intensity? Respirology. 2016;21(7):1185–1192. doi:10.1111/resp.12864
   PubMed Web of Science ®Google Scholar
• Hunter GR, Singh H, Carter SJ, Bryan DR, Fisher G. Sarcopenia and its implications for metabolic health. J Obes. 2019;2019:8031705. doi:10.1155/2019/8031705
   PubMed Web of Science ®Google Scholar
• Dilektasli AG, Porszasz J, Stringer WW, Casaburi R. Physiologic effects of oxygen supplementation during exercise in chronic obstructive pulmonary disease. Clin Chest Med. 2019;40(2):385–395. doi:10.1016/j.ccm.2019.02.004
   PubMed Web of Science ®Google Scholar
• Alison JA, McKeough ZJ, Leung RWM, et al. Oxygen compared to air during exercise training in COPD with exercise-induced desaturation. Eur Respir J. 2019;53(5):1802429. doi:10.1183/13993003.02429-2018
   PubMed Web of Science ®Google Scholar
• Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev. 2016;10:CD009419. doi:10.1002/14651858.CD009419.pub3
   PubMedGoogle Scholar
• Wu X, Hu X, Hu W, Xiang G, Li S. Effects of neuromuscular electrical stimulation on exercise capacity and quality of life in COPD patients: a systematic review and meta-analysis. Biosci Rep. 2020;40(5). doi:10.1042/BSR20191912
   Web of Science ®Google Scholar
• Sillen MJ, Franssen FM, Delbressine JM, Vaes AW, Wouters EF, Spruit MA. Efficacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and quadriceps muscle weakness: results from the DICES trial. Thorax. 2014;69(6):525–531. doi:10.1136/thoraxjnl-2013-204388
   PubMed Web of Science ®Google Scholar
• Landi F, Sieber C, Fielding RA, Rolland Y, Guralnik J. Nutritional intervention in sarcopenia: report from the international conference on frailty and sarcopenia research task force. J Frailty Aging. 2018;7(4):247–252. doi:10.14283/jfa.2017.26
   PubMed Web of Science ®Google Scholar
• Marco E, Sanchez-Rodriguez D, Davalos-Yerovi VN, et al. Malnutrition according to ESPEN consensus predicts hospitalizations and long-term mortality in rehabilitation patients with stable chronic obstructive pulmonary disease. Clin Nutr. 2019;38(5):2180–2186. doi:10.1016/j.clnu.2018.09.014
   PubMed Web of Science ®Google Scholar
• Yoneda T, Yoshikawa M, Fu A, Tsukaguchi K, Okamoto Y, Takenaka H. Plasma levels of amino acids and hypermetabolism in patients with chronic obstructive pulmonary disease. Nutrition. 2001;17(2):95–99. doi:10.1016/S0899-9007(00)00509-8
   PubMed Web of Science ®Google Scholar
• Sergi G, Coin A, Marin S, et al. Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med. 2006;100(11):1918–1924. doi:10.1016/j.rmed.2006.03.008
   PubMed Web of Science ®Google Scholar
• Baum JI, Kim IY, Wolfe RR. Protein consumption and the elderly: what is the optimal level of intake? Nutrients. 2016;8(6):359. doi:10.3390/nu8060359
   PubMed Web of Science ®Google Scholar
• Rondanelli M, Klersy C, Terracol G, et al. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. Am J Clin Nutr. 2016;103(3):830–840. doi:10.3945/ajcn.115.113357
   PubMed Web of Science ®Google Scholar
• Wood LG. Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease. Curr Opin Clin Nutr Metab Care. 2015;18(2):128–132. doi:10.1097/MCO.0000000000000142
   PubMed Web of Science ®Google Scholar
• Fulton AS, Hill AM, Williams MT, Howe PRC, Coates AM. Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review. Nutr Rev. 2015;73(9):612–623. doi:10.1093/nutrit/nuv017
   PubMed Web of Science ®Google Scholar
• Collins PF, Yang IA. Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. J Thorac Dis. 2019;11(Suppl 17):S2230–S2237. doi:10.21037/jtd.2019.10.41
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, Schols AM. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005;60(5):376–382. doi:10.1136/thx.2004.030858
   PubMed Web of Science ®Google Scholar
• Calder PC, Laviano A, Lonnqvist F, Muscaritoli M, Öhlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. J Cachexia Sarcopenia Muscle. 2018;9(1):28–40. doi:10.1002/jcsm.12228
   PubMed Web of Science ®Google Scholar
• Zhu M, Wang T, Wang C, Ji Y. The association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:2597–2607. doi:10.2147/COPD.S101382
   PubMed Web of Science ®Google Scholar
• Remelli F, Vitali A, Zurlo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients. 2019;11(12):2861. doi:10.3390/nu11122861
   PubMed Web of Science ®Google Scholar
• Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019;74(4):337–345. doi:10.1136/thoraxjnl-2018-212092
   PubMed Web of Science ®Google Scholar
• Calder PC, Laviano A, Lonnqvist F, Muscaritoli M, Ohlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. J Cachexia Sarcopenia Muscle. 2018;9(1):28–40.
   PubMed Web of Science ®Google Scholar
• Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14(8):542–559. doi:10.1016/j.jamda.2013.05.021
   PubMed Web of Science ®Google Scholar
• Pan L, Wang M, Xie X, Du C, Guo Y, Aggarwal AN. Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. PLoS One. 2014;9(1):e84855. doi:10.1371/journal.pone.0084855
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Zhang W, et al. Testosterone replacement therapy and hospitalization rates in men with COPD. Chron Respir Dis. 2019;16:1479972318793004. doi:10.1177/1479972318793004
   Web of Science ®Google Scholar
• Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest. 2003;124(5):1733–1742. doi:10.1378/chest.124.5.1733
   PubMed Web of Science ®Google Scholar
• Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(8):870–878. doi:10.1164/rccm.200305-617OC
   PubMed Web of Science ®Google Scholar
• Pape GS, Friedman M, Underwood LE, Clemmons DR. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest. 1991;99(6):1495–1500. doi:10.1378/chest.99.6.1495
   PubMed Web of Science ®Google Scholar
• Rolland Y, Onder G, Morley JE, Gillette-Guyonet S, Abellan van Kan G, Vellas B. Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med. 2011;27(3):423–447. doi:10.1016/j.cger.2011.03.008
   PubMed Web of Science ®Google Scholar
• Collden G, Tschop MH, Muller TD. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017;18(4):798. doi:10.3390/ijms18040798
   PubMed Web of Science ®Google Scholar
• Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65(9):1988–1995. doi:10.1111/jgs.14927
   PubMed Web of Science ®Google Scholar
• Polkey MI, Praestgaard J, Berwick A, et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. a randomized trial. Am J Respir Crit Care Med. 2019;199(3):313–320. doi:10.1164/rccm.201802-0286OC
   PubMed Web of Science ®Google Scholar
• Tonnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22(127):37–43. doi:10.1183/09059180.00007212
   PubMedGoogle Scholar
• Tashkin DP. Smoking cessation in chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2015;36(4):491–507. doi:10.1055/s-0035-1555610
   PubMed Web of Science ®Google Scholar
• Degens H, Gayan-Ramirez G, van Hees HW. Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms. Am J Respir Crit Care Med. 2015;191(6):620–625. doi:10.1164/rccm.201410-1830PP
   PubMed Web of Science ®Google Scholar
• Ajime TT, Serre J, Wust RCI, et al. Two weeks smoking cessation reverses cigarette smoke-induced skeletal muscle atrophy and mitochondrial dysfunction in mice. Nicotine Tob Res. 2020. doi:10.1093/ntr/ntaa016
   Web of Science ®Google Scholar
• Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. doi:10.1164/rccm.201706-1288OC
   PubMed Web of Science ®Google Scholar
• Di Marco F, Sotgiu G, Santus P, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19(1):18. doi:10.1186/s12931-018-0721-3
   PubMed Web of Science ®Google Scholar
• Joassard OR, Durieux AC, Freyssenet DG. Beta2-adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol. 2013;45(10):2309–2321. doi:10.1016/j.biocel.2013.06.025
   PubMed Web of Science ®Google Scholar
• Koopman R, Ryall JG, Church JE, Lynch GS. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders. Curr Opin Clin Nutr Metab Care. 2009;12(6):601–606. doi:10.1097/MCO.0b013e3283318a25
   PubMed Web of Science ®Google Scholar
• Hostrup M, Reitelseder S, Jessen S, et al. Beta2-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. J Physiol. 2018;596(17):4121–4139. doi:10.1113/JP275560
   PubMed Web of Science ®Google Scholar
• Mineo D, Ambrogi V, Lauriola V, Pompeo E, Mineo TC. Recovery of body composition improves long-term outcomes after lung volume reduction surgery for emphysema. Eur Respir J. 2010;36(2):408–416. doi:10.1183/09031936.00142309
   PubMed Web of Science ®Google Scholar
• Sanders KJC, Klooster K, Vanfleteren L, Slebos DJ, Schols A. CT-derived muscle remodelling after bronchoscopic lung volume reduction in advanced emphysema. Thorax. 2019;74(2):206–207. doi:10.1136/thoraxjnl-2018-211931
   PubMed Web of Science ®Google Scholar
• Shah S, Darekar B, Salvi S, Kowale A. Quadriceps strength in patients with chronic obstructive pulmonary disease. Lung India. 2019;36(5):417–421. doi:10.4103/lungindia.lungindia_27_19
   PubMed Web of Science ®Google Scholar
• Billot M, Calvani R, Urtamo A, et al. Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, challenges, and recommendations for physical activity interventions. Clin Interv Aging. 2020;15:1675–1690. doi:10.2147/CIA.S253535
   PubMed Web of Science ®Google Scholar